First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study

Gherghel, Doina; Hosking, Sarah; Cunliffe, I A; Armstrong, Richard A.

doi:10.1038/sj.eye.6702639

Cited by 15 publications

(10 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Harris et al (2008), using Heidelberg Retinal Flowmetry and Color-Doppler imaging measurements (including peak systolic velocity and end diastolic velocities), found that latanoprost has mostly neutral effects on ocular circulation, heart rate and blood pressure in healthy subjects. This is in contrast with the results found by Gherghel et al (2008), which shows that latanoprost increases mean ocular perfusion pressure (MOPP) and improves ocular perfusion at the optic nerve head and retina levels, measured with Heidelberg Retina Flowmeter system. DOPP assessment is interesting, since a low DOPP (Ͻ55 mmHg) is associated with an increased prevalence and incidence of glaucoma (Quigley et al 2001;Leske et al 2002).…”

Section: Effects On Blood Fl Owcontrasting

confidence: 99%

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Quaranta¹

2009

OPTH

View full text Add to dashboard Cite

Latanoprost is a prostaglandin F2-alpha isopropyl ester prodrug which is rapidly hydrolyzed by esterases in the cornea to the biologically active latanoprost acid. When latanoprost is topically administered into the eye, the cornea seems to act like as a slow-release depot to the anterior segment. One hour after administration maximum concentration is found in the iris, followed by the anterior chamber and the ciliary body. Despite extensive research, controversy remains about the real mechanism of action of this drug. Immunohistochemical data have shown that the intraocular pressure (IOP) reduction with topical prostaglandin F2-alpha is associated with a reduction of collagens within the uveoscleral outfl ow pathway. Evidence from several experimental and clinical studies suggests that latanoprost is a valuable addition fi rst-line treatment alternatives for glaucoma, ocular hypertension and even angle-closure glaucoma. Strong points are its effi cacy, which is demonstrated to be higher than that of brimonidine, dorzolamide and timolol with fewer systemic adverse effects; a convenient administration schedule; and the IOP-controlling pattern, which is relatively fl at compared with timolol and dorzolamide, and enables better control in glaucoma progression, since large fl uctuations may be associated with the risk of developing glaucoma in untreated ocular hypertensive subjects.

show abstract

Section: Effects On Blood Fl Owcontrasting

confidence: 99%

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Quaranta¹

2009

OPTH

View full text Add to dashboard Cite

show abstract

“…2004; Koz et al. 2007; Gherghel et al. 2008), whereas in other studies, the ocular perfusion pressure was found to be unchanged (Nicolela et al.…”

Section: Discussionmentioning

confidence: 79%

Topical treatment for 1 week with latanoprost but not diclofenac reduces the diameter of dilated retinal arterioles in patients with type 1 diabetes mellitus and mild retinopathy

Tilma

Bek

2011

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: Diabetic retinopathy is characterised by morphological lesions secondary to retinal vascular impairment, and it is assumed that changes in the diameter regulation of retinal arterioles are involved in the disease pathogenesis. It has previously been shown that prostaglandin F2a can constrict retinal arterioles in vitro. In the present study, we investigated whether a similar effect could be achieved by topical administration in diabetic patients with dilated retinal arterioles and retinopathy. Methods: Twenty-two type 1 diabetic patients with mild retinopathy and twenty-four matched normal controls were randomized to topical treatment with the prostaglandin F2a agonist latanoprost twice daily for 1 week, followed by similar treatment with the cyclo-oxygenase inhibitor diclofenac, or to receive the two medications in the reverse order. The Dynamic Vessel Analyzer was used to assess the effect of the interventions on the resting diameter of retinal vessels and on the diameter response of retinal arterioles to increased blood pressure (BP) induced by isometric exercise and flicker stimulation. Results: Latanoprost reduced the resting diameter of retinal arterioles significantly in patients with diabetes (p = 0.01), but had no effect on normal persons. Diclofenac had no effect on the resting diameter of arterioles in either of the groups. The diameter responses to increased BP and flicker stimulation were not significantly changed by any of the treatments. Conclusion: Long-term prospective studies are needed to study the effect of topical treatment with latanoprost on the consequences of retinal hyperperfusion in retinal vascular diseases such as diabetic retinopathy.

show abstract

“…The published effects of latanoprost on OBF are also heterogeneous. Whereas some authors have found a neutral effect on OBF in healthy subjects33 and in patients with primary open-angle glaucoma,28,34–37 others have described an increase of OBF in heathy volunteers38 and in patients with primary open-angle glaucoma 33,39. In ex vivo studies, latanoprost reduced the endothelin-induced vasoconstriction of isolated rabbit ciliary arteries40 and in in vivo studies with rabbits, latanoprost mitigated the endothelin-induced reduction of optic nerve head blood flow 40.…”

Section: Discussionmentioning

confidence: 99%

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature

Konieczka

Koch

Hauenstein

et al. 2019

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose The aim of this study was to investigate the effects of the glaucoma drugs latanoprost, brimonidine, and the combination of both on the central corneal temperature (CT) of healthy subjects by means of infrared thermography. Changes of the central CT may reflect changes of ocular blood flow. Methods Before application and during 2 hours after the application of latanoprost, brimonidine, or the combination of both in one eye, the CT in both eyes of 40 healthy subjects was measured repeatedly. Results Brimonidine reduced CT by approximately 0.5°C. This effect was statistically significant ( P < 0.0001). Latanoprost, however, had a very small and insignificant influence ( P = 0.47). Accordingly, the combination of brimonidine and latanoprost also reduced CT up to 0.5°C, and this effect was statistically significant ( P < 0.0001). Conclusions Brimonidine, but not latanoprost, had a significant effect on central CT. This cooling effect of brimonidine is most probably due to a drug-induced reduction of blood circulation in the ciliary body and iris and to a certain extent also to a reduction of blood flow in the fundus of the eye. Translational Relevance This study shows evidence that thermography of the cornea provides indirect information on the influence of drugs on the blood flow to the anterior segment of the patient's eye.

show abstract

First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study

Cited by 15 publications

References 58 publications

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

Topical treatment for 1 week with latanoprost but not diclofenac reduces the diameter of dilated retinal arterioles in patients with type 1 diabetes mellitus and mild retinopathy

Effects of the Glaucoma Drugs Latanoprost and Brimonidine on Corneal Temperature

Contact Info

Product

Resources

About